Overview Of Endometrial Cancer: Global Clinical Trials Landscape

Uterine cancer, primarily endometrial cancer, is the fourth leading cause of gynecological cancer-related deaths worldwide. Significant risk factors for developing endometrial cancer include prolonged estrogen exposure, early menarche, late menopause, nulliparity, obesity, hypertension, diabetes, estrogen-only hormone replacement therapy (HRT), and genetic syndromes such as Lynch and Cowden.

This FAQ delves into the latest developments in endometrial cancer treatment. It highlights innovative drugs, ongoing clinical trials, and their potential impact on patient outcomes. Recent advances in targeted therapies and immunotherapies are offering new hope for patients. For instance, the FDA has approved new treatments like dostarlimab-gxly and pembrolizumab combined with lenvatinib, which have shown promise in managing advanced and recurrent cases.

Moreover, we explore the global landscape of clinical trials aimed at improving endometrial cancer care. With over 1,200 trials initiated since 2018, research efforts are robust, particularly in North America and Asia-Pacific. These trials are investigating a range of therapeutic approaches, including novel drug combinations and personalized medicine strategies.